Abstract Aim: Lymph node metastases influence prognosis and outcome in patients with bladder and prostate cancer. Cross sectional imaging criteria are limited in detecting metastases in normal sized lymph nodes. This prospective study assessed the diagnostic accuracy of ultrasmall superparamagnetic particles of iron oxide (USPIO)-enhanced magnetic resonance imaging (MRI) for the detection of metastases in normal sized lymph nodes using extended pelvic lymph node dissection (ePLND) and histopathology as the reference standard. Methods: Seventy-five patients (bladder cancer, n = 19, prostate cancer n = 48, both, n = 8) were examined using 3T MR before and after USPIO-administration. A preoperative reading with two readers in consensus and a second postoperative reading with three independent blinded readers were performed. Results were correlated with histopathology and diagnostic accuracies were calculated for all readings. Results: A total of 2993 lymph nodes were examined histopathologically. Fifty-four metastatic nodes were found in 20/75 patients (26.7%). The first reading had a sensitivity of 55.0%, specificity of 85.5%, positive predictive value (PPV) of 57.9%, negative predictive value (NPV) of 83.9%, and diagnostic accuracy (DA) of 77.3% on a per patient level. The second reading had a mean sensitivity of 58.3%, specificity of 83.0%, PPV of 58.0%, NPV of 84.4% and DA of 76.4% on a per patient level. The majority of missed metastases were smaller than 5 mm in short axis diameter. Conclusions: USPIO-enhanced MRI in bladder and prostate cancer patients allows detection of metastases in normal sized lymph nodes and might guide the surgeon to remove suspicious lymph nodes not included in standard PLND.
Introduction
Metastatic involvement of lymph nodes in patients with bladder and/or prostate cancer has a strong impact on treatment decisions and patient prognosis. [1] [2] [3] [4] [5] Although size and morphology are used to evaluate lymph node involvement using conventional cross sectional imaging, there is a limited ability to detect metastases in normal sized lymph nodes using these criteria. Therefore, an extended template pelvic lymph node dissection (ePLND) is preferred by many urologists, even when no lymph node metastases are detectable on computerised tomography (CT) or magnetic resonance imaging (MRI) (N0 staging). [6] [7] [8] In fact, occult lymph node metastases are found in template lymphadenectomy in up to 25% of patients staged as N0. 5, 7, 9, 10 It is also known that lymph node metastases in patients with bladder and/or prostate cancer do not necessarily follow a predefined pathway of spread, 11 and that even when PLND is extended to the mid-upper third of the common iliac vessels, only about 90% of the primary lymphatic landing sites are removed. [6] [7] [8] 12 Thus, ePLND remains the gold standard for the detection of lymph node metastases in patients with urogenital cancers. [13] [14] [15] [16] Although restricted lymph node dissection and targeted local treatments are desirable, these can only be performed if accurate preoperative lymph node staging is possible.
In order to improve detection of lymph node metastases, the use of lymphotropic ultrasmall superparamagnetic particles of iron oxide (USPIO) has been investigated in several urogenital malignancies. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] Promising results with apparent diagnostic accuracies up to 97.3% have been published; however, none of the previous studies were based on ePLND. Therefore, the accuracy of the published negative predictive values is limited. Moreover, the majority of the published studies included patients with enlarged lymph nodes, and few authors commented on the detection of metastases in normal sized lymph nodes after the administration of USPIO. 18, 26 Thus, the aim of our study was to prospectively assess the diagnostic accuracy of USPIO-enhanced MRI for the detection of lymph node metastases in bladder and/or prostate cancer patients with N0 staging based on conventional MR/CT imaging using meticulous ePLND and histopathology as the reference standard.
Methods

Patients
Between May 2008 and March 2010, 256 patients with histologically proven invasive bladder and/or prostate cancer were scheduled for radical cysto-/prostatectomy and ePLND (Fig. 1) . Patients with prior chemotherapy or radiotherapy in the pelvic area, enlarged pelvic lymph nodes on previous CT/MRI (threshold of 10 mm in short axis diameter for bladder and 8 mm for prostate cancer), positive bone scintigraphy, hemochromatosis, gadolinium administration 48 h prior to the examination, known iron or dextrane allergy or MR contraindications were excluded. Finally, 84 of these patients were initially eligible for study inclusion.
Nine of these 84 patients were secondarily excluded due to the detection of bone metastases on study MRI contraindicating surgery (n = 1), detection of enlarged lymph nodes on the MR images (n = 2), unacceptable image quality (n = 1), inductive chemotherapy following positive imaging results (n = 2), allergic reaction to USPIO (n = 1), refusal of surgery (n = 1) or cancellation of surgery due to poor performance status (n = 1). A total of 75 patients qualified for final image analysis and represented the study cohort (Table 1) .
Imaging
All patients were examined on a 3T MR unit (Trio, Siemens Medical, Erlangen, Germany). Two identical pelvic MRI exams were performed before and 24-36 h after intravenous administration of 2.6 mg iron/kg body weight of USPIO (Ferumoxtran-10, Sinerem Ò ; Guerbet, Roissy, France). One milligram of Glucagon (GlucaGen, Novo Nordisk, Switzerland) was administrated intravenously at the beginning of each MR exam. Adverse events such as urticaria (n = 2), hot flash, hypertension and headache (n = 2), swelling of neck and nose (n = 1) and diarrhoea (n = 2) occurred in seven (11%) patients. In an eighth patient USPIO injection was stopped when dyspnoea and hypertension occurred after injection of 2 ml USPIO solution. Symptoms were selflimiting in all cases.
A 3D T1-weighted (T1w) sequence with 0.8 mm 3 reconstructed isotropic voxels, and an iron-sensitive 3D T2-weighted (T2w) sequence with 1.0 mm 3 isotropic voxels were performed in the coronal plane through the entire pelvis. In addition, a 3D T1w-VIBE sequence was obtained during the second MRI exam to facilitate the exact anatomical localisation of the lymph nodes in relation to the blood vessels. Additional diffusion-weighted MRI sequences were performed but not evaluated in the present study.
Radiological evaluation
Radiological evaluation was performed on a picture archiving and communication system (PACS) workstation (PACS R11.4.1, 2009; Philips, Best, Netherlands; Sectra, Linkö ping, Sweden). A preoperative reading was performed by two readers in consensus out of a pool of four (M.T., H.C.T., G.P., J.M.F. with 3, 12, 5 and 8 years of experience in body MRI, respectively). After finishing the patient accrual a second postoperative reading was performed by three readers independently (G.P., A.C. and M.T.), blinded to histopathology results and clinical information. Reader A (G.P.) was a radiologist with six years of MRI experience and one year of experience in USPIO-enhanced MRI, Reader B (A.C.) had five years of experience in MRI and a short training Abbreviations: MR = magnetic resonance; LN = lymph nodes.
in reading USPIO-enhanced MRI. Reader C (M.T.) was a radiologist with five years of MRI experience and two years of USPIO-enhanced MRI experience.
Image interpretation
A node-by-node analysis was performed on axially reconstructed (2 mm slices) T2w-sequences by comparing images before and after USPIO-administration. Lymph nodes were considered benign when a signal intensity loss of >15% on the post-USPIO images was observed, 27 and malignant when signal intensity was largely maintained in areas which did not correspond to hilar fat (Fig. 2) . Localisation of suspicious nodes was indicated on an anatomical landmark chart dividing the pelvis into ten regions (Fig. 3) . Imaging results were reviewed with the responsible surgeon after the first reading to ensure removal of suspicious lymph nodes.
The entire time of evaluation was noted for all readings.
Surgery
Prior to PLND, lymph nodes indicated on the landmark chart were resected, labelled and sent for separate histopathological examination. An ePLND including the area of the crossing of the ureters and the common iliac vessels was then performed. 6, 12 Specimens from ePLND were labelled according to the ten anatomical regions.
Histopathological evaluation
Resected lymph nodes were fixed overnight in 4% formalin, degreased with acetone, cut into 2-4 mm thick tissue slices and completely embedded in paraffin. One section per paraffin block was taken for histopathological examination. Two experienced pathologists evaluated histopathological findings that could influence the uptake of USPIO in each lymph node, including follicular hyperplasia, sinus histiocytosis, marked fibrosis, Fig. 2 . Typical example of ultrasmall superparamagnetic particles of iron oxide (USPIO) uptake in positive and negative lymph nodes. Axial T2w-reconstructed images before (A) and after (B) the administration of USPIO in a 67-year-old prostate cancer patient. The benign lymph node (black arrow) shows a decrease in signal intensity after the uptake of USPIO; the malignant lymph node (white arrow) shows only partial posterior and medial signal decrease after the administration of USPIO. Fig. 3 . Anatomic landmark chart divided into 10 regions according to the iliac vessels: common iliac right (3) and left (6), proximal external iliac right (1b) and left (4b), distal external iliac right (1a) and left (4a), proximal internal iliac right (2b) and left (5b), distal internal iliac right (2a) and left (5a). marked fatty involution and neoplastic tissue. Sizes of positive lymph nodes and metastases were measured in two planes and localisations on the anatomic landmark chart were recorded.
Statistics
All included patients were staged N0. Statistical performance measures (i.e. sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy) of the USPIO readings as compared to histopathological findings were calculated both on a per patient and per pelvic side level for both readings.
Statistical analyses were performed using Microsoft Excel with the Analyse-it plugin (Release 2.22/2010; Analyse-it Software Ltd., Leeds, United Kingdom; Microsoft, Redmont, USA). Receiver operating characteristic (ROC) curve analyses were performed using histopathological results as gold standard (Fig. 4) .
Interobserver agreement between the three blinded readers in the second reading was assessed on a per patient level using Fleiss's kappa statistic and Randolph's freemarginal multirater kappa statistic for all four readings, where a kappa of 1.0 indicates perfect agreement. 28, 29 3. Results
Histopathological evaluation
A total of 2993 lymph nodes were identified in 75 patients. Fifty-four metastases (1.8% of resected lymph nodes) were found in 20/75 (26.7%) patients. Thirteen patients presented with unilateral metastases (Table 2) . Histopathology reported four metastatic lymph nodes having a short axis diameter >10 mm. Most of the malignant lymph nodes had a short axis diameter 65 mm (41/54) (Fig. 5) . The majority of the metastases themselves had a short axis diameter 65 mm (50/54), and 43/54 were 63 mm in short axis diameter (Table 3) . Table 2 Patients with unilateral and bilateral pelvic lymph node metastases. Results are similar for long axis diameter measurements (Table 3) .
Diagnostic performance on a per patient level
In the first reading a sensitivity of 55.0%, specificity of 85.5%, PPV of 57.9%, NPV of 83.9% and diagnostic accuracy (DA) of 77.3% were observed (Table 4) , and 11/20 patients were correctly diagnosed as positive. In the second reading, combining the results of all three independent readers gave a mean sensitivity of 58.3%, mean specificity of 83.0%, mean PPV of 58.0%, mean NPV of 84.4% and mean DA of 76.4% (Table 4) . Readers A, B and C correctly detected metastases in 11/20, 11/20 and 13/20 patients, respectively, and gave false negative readings in 9/20, 9/20 and 7/20 patients (Table 4 ).
Diagnostic performance on a per pelvic side level
On a per pelvic side level (n = 150) a sensitivity of 46.2%, specificity of 89.5%, PPV of 48.0%, NPV of 88.8% and DA of 82.0% were reported in the first reading. Metastases were correctly detected in 12/26 positive sides. In the second reading a mean sensitivity of 50.0%, specificity of 88.4%, PPV of 50.0%, NPV of 89.4% and DA of 81.8% were observed for readers A, B and C, respectively (Table 5) .
Detection of small metastases
Apart from one metastasis with a short axis diameter of >5 mm which was missed by one reader, all other missed metastases were 65 mm, and most were 63 mm in short axis diameter. A total of 17 metastases with a short axis diameter 65 mm were correctly detected by the most experienced reader. Some anatomical regions were particularly difficult to evaluate for small (65 mm) metastases, including the perivesical and periprostatic area and lymph nodes along the common iliac vessels. A periprostatic metastasis of 0.5 Â 0.2 mm and a metastasis in the perivesical fat of 0.28 Â 0.28 mm were missed in all four readings. Small metastases close to the common iliac vessels also remained undetected in all four readings (Table 5 and Fig. 6 ).
False positive results could be attributed in single cases to marked fibrosis or lipomatosis (Fig. 7) .
Interobserver agreement of second reading
Interrater agreement for the four readings yielded a Fleiss' kappa of 0.77 and a Randolph's multirater kappa of 0.54, indicating a moderate interrater agreement. 
Time of evaluation for the MRI readings
The time of evaluation for the preoperative MRI reading ranged from 10 to 93 min with a median value of 45 min per patient and for the second reading from 10 to 47 min with a median of 32 min per patient.
Discussion
Our results indicate that USPIO-enhanced MRI enables detection of lymph node metastases in normal sized lymph nodes in bladder and prostate cancer patients staged as metastasis free (N0) based on conventional cross sectional imaging methods. These results are in agreement with previously published data which show that USPIO-enhanced MRI improves pelvic lymph node staging in patients with urogenital malignancies. [18] [19] [20] 26 Despite the limited spatial resolution of MRI, we were even able to detect lymph node metastases smaller than 5 mm. Using ePLND as reference standard, the results of the present study provide an accurate portrayal of the diagnostic potential of USPIO-enhanced MRI. Due to the still substantial number of false negative readings, USPIO-enhanced MRI cannot replace ePLND. However, we have demonstrated that USPIOenhanced MRI provides valuable additional information which could guide the surgeon to extend the region of standard PLND.
The diagnostic accuracies reported here are relatively low compared to previous literature. This may be partially attributed to the exclusion of patients with enlarged lymph nodes from this study. In a study including bladder cancer patients, those authors found 38/50 positive lymph nodes larger than 10 mm. 26 In another study including prostate cancer patients, 38/63 positive nodes fulfilled the morphological imaging criteria of malignancy. 18 The inclusion of lymph nodes with suspicious morphology partially explains the higher sensitivity and positive predictive values reported in these studies. Although our final histopathological results showed four metastatic nodes having a short axis diameter >10 mm, these nodes were not detectable on retrospective review of the MR images. This may be related to the differing planes of MR imaging and histopathological sectioning.
Another strength of the present study is the high number of lymph nodes that were resected (mean of 39 per patient) explaining the lower diagnostic accuracy compared to previous studies. 6, 12 Additionally, a meticulous histopathological analysis of each lymph node lead to the detection of micrometastases as small as 0.1 Â 0.2 mm. This is significant because the likelihood that micrometastases will be found increases with the number of normal sized nodes removed 7 and the sensitivity of our diagnostic assays was correspondingly lower. In a study of prostate cancer patients, 334 lymph nodes were resected or biopsied in 80 patients which corresponds to an average of four nodes per patient, suggesting that primarily enlarged nodes and nodes suspicious for metastases on USPIO-enhanced MRI were analysed. 18 This results in an overestimation of the diagnostic accuracy since the number of missed metastases in normal sized LNs is unknown in the absence of histopathological results.
As in previously published literature, 18, 19 false positive results were often found in conjunction with conditions influencing the normal architecture and function of lymph nodes such as fibrosis, sinus histiocytosis, lipomatosis or focal fatty involution which may lead to heterogeneous uptake of USPIO. However, from a clinical point of view, false positive findings are of lesser importance than false negatives since the removal of false positive nodes does not harm the patient, while missing metastatic nodes can negatively impact patient prognosis. Thus, the relatively high negative predictive value on a per patient level in our study demonstrates the potentially useful role of USPIO-enhanced MRI in patient management.
In contrast to previous studies, our investigation was performed on a 3T MR unit providing improved image quality relative to 1.5T MR. This allowed for high image resolution with reconstructed isotropic voxel sizes as small as 0.8 mm 3 , which was crucial to the detection of small metastases. However, the majority of metastases with a short axis diameter 63 mm were still missed.
Our study has several limitations. Firstly, node-by-node correlations of MRI with histopathology could not be performed. However, the localisation of lymph nodes in ten well defined anatomical regions allowed nodes seen on MRI to be targeted surgically. Secondly, we refrained from individual analysis of the ten sectors as initially planned, because the boundaries of surgical resection were ill defined and varied depending on the individual surgeon. Therefore, we performed our analysis per pelvic side and per patient. Thirdly, although ePLND was performed with a high number of lymph nodes resected per patient, it is possible that single lymph nodes were missed.
Finally, it must be mentioned that USPIO is not currently approved by health authorities for lymph node detection, despite several attempts and a large number of clinical studies. In anticipation of the development of further USPIO-derivatives, we believe that the present study is important in providing insight into the diagnostic work-up of lymph node metastases and in setting realistic and clinically relevant imaging goals for future studies.
The present data show that the use of USPIOenhanced MRI in patients with bladder and/or prostate cancer staged as N0 on conventional cross sectional imaging enables the accurate detection of metastases with a short axis diameter of 5 mm and larger. Due to the number of missed metastases smaller than 3 mm, lymph node dissection restricted to suspicious nodes cannot be recommended. However, USPIO-enhanced MRI has the potential to improve treatment and patient outcomes by guiding the removal of additional suspicious nodes in pelvic regions not typically included in standard PLND.
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